Why C4IP Opposes the Drug Competition Enhancement Act and the Affordable Prescriptions for Patients Act
Congress is currently considering several ill-conceived bills that purport to address abuses in the patent system, but would, in reality, weaken core intellectual property protections. Among them are the Drug Competition Enhancement Act (S. 1040) and the Affordable Prescriptions for Patients Act (S. 1041). By attempting to devalue the United States’ robust intellectual property system, […]